TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

Tang Capital Management, LLC announces that on June 2, 2026, it acquired 206,005 common shares (the "Common Shares") of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the "Issuer") at a price of US $15.28 per share (approximately CAD $21.13 per share) for an aggregate purchase price of US $3.1 million (approximately CAD $4.35 million) by way of the public market.

Immediately prior to the transaction, Tang Capital Management, LLC held 12,838,101 Common Shares of the Issuer. As a result of the purchase, Tang Capital Management, LLC beneficially owns 13,044,106 Common Shares, representing approximately 10.0% of the issued and outstanding Common Shares of the Issuer immediately following June 2, 2026.

This news release is issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues of the Canadian Securities Administrators, which also requires an early warning report to be filed with the applicable securities regulators containing additional information with respect to the foregoing matters. A copy of the early warning report filed by Tang Capital Management, LLC will be available under the Issuer's profile on SEDAR+ at www.sedarplus.ca or by contacting Michael Hearne, Chief Financial Officer at (858) 200-3830. The Tang Capital Management, LLC head office is located at 4747 Executive Drive, Suite 210, San Diego, CA 92121.

SOURCE Tang Capital Management, LLC

Cision View original content: http://www.newswire.ca/en/releases/archive/June2026/03/c8929.html

News Provided by Canada Newswire via QuoteMedia

AUPH
The Conversation (0)
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC). Under U.S. federal securities laws, equity awards issued as employee compensation must be... Keep Reading...
Aurinia Announces 2023 Annual General Meeting Results

Aurinia Announces 2023 Annual General Meeting Results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two... Keep Reading...
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS®  AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up Activity scores... Keep Reading...
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual Property Conference... Keep Reading...
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®  For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed... Keep Reading...

Interactive Chart

Latest Press Releases

Related News